Neuraxpharm’s partner, Minoryx Therapeutics, has this week presented a poster entitled ‘Efficacy and safety of leriglitazone treatment in male paediatric patients with cerebral X-linked adrenoleukodystrophy: interim results from the NEXUS study’ at the 12th European Conference on Rare Diseases and Orphan Products (ECRD 2024).
The hybrid event took place from 15-16 May and attendees came together from across Europe and beyond to highlight research in rare diseases and bring together stakeholders in the rare disease community.
Find out more about the event here and view Minoryx’s poster online at: https://www.rare-diseases.eu/